Lilly drug cuts some breast cancer risk-FDA staff

(Reuters) - Evista is already approved to treat osteoporosis in women
past menopause. The company is seeking approval to promote the
drug for the reduction in risk of invasive breast cancer in
postmenopausal women with osteoporosis and postmenopausal women
at high risk for breast cancer.




Studies provide less support for the proposed new use to
reduce the chances of invasive breast cancer in postmenopausal
women at high risk, FDA reviewers said.



Read more at Reuters.com Government Filings News